|
Eurand Stage: Spin-outs Date of Investment: 1999 Web Site : http://www.eurand.com Stock Symbol : Nasdaq: EURX |
 |
Eurand, headquartered in Milan, Italy, is a leading specialty pharmaceutical company that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products. The Company operates from integrated research, development and production facilities in Italy, France and North America, and utilizes proprietary pharmaceutical technologies to develop novel products that have advantages over existing products or address unmet medical needs. Through collaboration arrangements with leading pharmaceutical companies, the Company has successfully applied its portfolio of existing and new technologies to drug products in a diverse range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. Eurand is currently developing and commercializing its own portfolio of therapeutic products to address conditions associated with cystic fibrosis and gastrointestinal disorders.
In partnership with management, Warburg Pincus acquired Eurand from American Home Products, Inc., now part of Pfizer, in 1999. Warburg Pincus subsequently invested additional funds into the Company, primarily to fund a number of acquisitions. Eurand completed its initial public offering on Nasdaq in May 2007 raising gross proceeds of $112 million.
